Back to results
US 2022/0017640 A1Published application
Activatable bispecific antibodies
AssigneeHoffmann-La Roche Inc.
InventorsUlrich BRINKMANN, Rebecca CROASDALE, Silke METZ, Juergen Michael SCHANZER, Claudio SUSTMANN, Pablo UMANA
Life of this patent
Estimating the term…
Abstract
The current invention relates to bispecific antibodies wherein the binding affinity to one of the two antigens is reduced and which can be activated by tumor- or inflammation-specific proteases, and the preparation and use of such bispecific antibodies.
Claims21
A bispecific antibody comprising
- a) a first antibody that binds to a first antigen comprising a VH1 domain and a VL1 domain, and
- b) a second antibody that binds to a second antigen,
- wherein the VH1 domain is fused N-terminally via a first peptide linker to the
- second antibody, and the VL1 domain is fused N-terminally via a second peptide linker to the second antibody, and
- characterized in that
- one of the linkers comprises a tumor- or inflammation-specific protease cleavage site, and the other linker does not comprise a protease cleavage site;
- and
- the binding affinity of the bispecific antibody to the first antigen is reduced 5 times or more compared to the corresponding bispecific antibody in which the protease cleavage site is cleaved.
5 more elements
19-22. (canceled)
(canceled)
Dependencies are inferred from the claim text.